Erdafitinib Tablets, FGFR3 Testing and Treatment Monitoring
A practical guide to the molecular test, tablet identity and monitoring questions that accompany erdafitinib treatment.
Reference table
Erdafitinib reference table
The catalogue has separate erdafitinib 3 mg, 4 mg and 5 mg presentations. Record the exact strength on the prescription and each tablet's identity. A specialist may prescribe more than one tablet to make up a daily amount. Changing the tablet count without the written plan can change exposure.
Understanding the tablet strengths
| Presentation | What the number describes | Information to confirm |
|---|---|---|
| 3 mg tablet | 3 mg in each tablet | Exact brand and prescribed tablet count |
| 4 mg tablet | 4 mg in each tablet | Exact brand and prescribed tablet count |
| 5 mg tablet | 5 mg in each tablet | Exact brand and prescribed tablet count |
The source product and country are identified in the article. Confirm personal treatment instructions with the prescribing clinician.
What erdafitinib treats in the reference label
Erdafitinib inhibits fibroblast growth factor receptors involved in cell signalling. The US BALVERSA prescribing information describes treatment for selected adults with locally advanced or metastatic urothelial carcinoma after prior systemic treatment. The label specifies susceptible FGFR3 genetic alterations and a companion diagnostic.
A cancer diagnosis alone does not establish eligibility. The molecular test, previous treatment and local indication all matter. The US label states that BALVERSA is not recommended for patients eligible for PD-1 or PD-L1 inhibitor therapy who have not yet received it. An Indian product listing should be checked against its own approved information.
Understanding the tablet strengths
The catalogue has separate erdafitinib 3 mg, 4 mg and 5 mg presentations. Record the exact strength on the prescription and each tablet's identity. A specialist may prescribe more than one tablet to make up a daily amount. Changing the tablet count without the written plan can change exposure.
The comparison identifies presentations. It does not set a starting dose or a dose-adjustment schedule.
Monitoring during treatment
The oncology service monitors phosphate and other blood results and arranges eye examinations. The US label specifies regular ophthalmological assessment and additional assessment for visual symptoms. Keep the appointments even when vision feels normal.
New blurred vision, visual distortion or other sight changes should be reported promptly. Diarrhea, mouth soreness, skin and nail changes and fatigue can also affect treatment. The team may interrupt or adjust therapy according to the actual findings. Record when a symptom began and which dose was being taken.
Medicines, pregnancy and missed-dose questions
Provide the oncology pharmacist with a complete list of medicines, supplements and phosphate-altering products. Interactions involving CYP enzymes and transport proteins can affect treatment. Ask the team before adding an antacid, vitamin, supplement or another prescribed medicine.
Erdafitinib can harm an unborn baby. Discuss pregnancy prevention, pregnancy testing and breastfeeding with the treating service. Follow the exact product's missed-dose instructions and contact the team when vomiting or repeated missed doses occur. Extra tablets should not be used to compensate without instruction.
Preparing a specialist product enquiry
An institutional enquiry can specify the ingredient, exact branded presentation, tablet strength, number of packs and destination. Ask for the pack image, manufacturer details, available leaflet, batch and expiry information and required supporting records before a quotation is finalised.
The receiving organisation should confirm the applicable supply route for the specific product. A molecular test report and medical history belong in the clinical team's secure process. An ordinary public sales form needs product specifications and an organisation's contact details, rather than sensitive patient records.
Product information for an enquiry
View Erdafitinib 3 mg Tablets, Erdafitinib 4 mg Tablets, Erdafitinib 5 mg Tablets for the listed formulations. Include the exact strength, dosage form, quantity and destination in a professional product enquiry.
Export product support
Need product, pack, and documentation details?
Global Medicines Export can support international B2B enquiries for product availability, strengths, pack information, quotation coordination, and shipment documentation review.
Common questions
Does the tablet strength establish the daily dose?
The prescription establishes the total amount and tablet count. A 3 mg or 4 mg label describes one tablet. The oncology service decides whether a dose change is appropriate.
Does every bladder cancer patient need erdafitinib?
Treatment selection depends on the tumour alteration, previous treatment and the locally authorised indication. The oncology team interprets those findings together.
Why are eye appointments needed?
The reference label describes retinal adverse effects. Regular examination and prompt reporting of new visual symptoms help the team assess treatment safety.
Does the BALVERSA reference approve another brand?
Each branded product and destination needs its own verification. The reference explains BALVERSA's US information and cannot establish another product's authorisation.
Important medical note
This article is for general educational information only. It is not medical advice, diagnosis, or a treatment plan. Medicines should be used only under the guidance of a qualified healthcare professional. Product availability, export documentation, and quotation support do not imply that a medicine is appropriate for any individual patient.